OneSource Specialty Pharma announced its partner Orbicular received Health Canada approval for a generic Ozempic® (semaglutide) injection.
This marks the second generic semaglutide approval in Canada, positioning OneSource partners as first generic entrants in this major market.
Commercial supply will be supported from OneSource's US FDA-approved Bengaluru facility, following recent US tentative approval.
CEO Neeraj Sharma highlighted the strength of their CDMO platform and compliance standards for complex drug-device combinations.